Methotrexate sodium

This classification denotes an antineoplastic antimetabolite, immunosuppressant, folic acid antagonist, and nucleic acid synthesis inhibitor with the molecular formula C20H20N8O5.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3IG1E710ZN, chemically known as glutamic acid, n-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-, disodium salt, l-(+)- but more generally known as methotrexate sodium, which bears US NIH Compound Identifier 23893. European Medicines Agency schedules Methotrexate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03225MIG. Most nations, for tariff and trade purposes, schedule methotrexate sodium under HS 29335995 and SITC 51576. As of Q4 2014, METHOTREXATE SODIUM remains US FDA's Preferred Term for this commodity. Methotrexate sodium bears US NLM identifiers UMLS ID C0949359 and NCI Concept Code C1735. SMILES: CN(CC1CNC2C(N1)C(NC(N2)N)N)C3CCC(CC3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[NA+].[NA+].